Cai Jiaying, Wang Jingting, Wang Zengping, Wang Jing, Jia Yanfei, Ma Xiaoli
Research Center of Basic Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Front Cell Dev Biol. 2025 Mar 12;13:1489958. doi: 10.3389/fcell.2025.1489958. eCollection 2025.
Nicotinic acetylcholine receptors (nAChRs) are widely expressed in a variety of cell types and are involved in multiple physiological regulatory mechanisms in cells, tissues and systems. Increasing evidence suggests that the α5 nicotinic acetylcholine receptor (α5-nAChR), encoded by the CHRNA5 gene, is one of a key mediator involved in lung cancer development and immune responses. Several studies have shown that it is a regulator that stimulates processes via various signaling pathways, including STAT3 in lung cancer. In addition, α5-nAChR has a profound effect on lung immune response through multiple immune-related factor pathways. In this review, we focus on the perspectives on α5-nAChR in lung cancer progression, which indicates that targeting α5-nAChR could provide novel anticancer and immune therapy strategies for lung cancer.
烟碱型乙酰胆碱受体（nAChRs）广泛表达于多种细胞类型中，并参与细胞、组织和系统中的多种生理调节机制。越来越多的证据表明，由CHRNA5基因编码的α5烟碱型乙酰胆碱受体（α5-nAChR）是参与肺癌发展和免疫反应的关键介质之一。多项研究表明，它是一种通过多种信号通路刺激相关过程的调节因子，包括肺癌中的信号转导和转录激活因子3（STAT3）。此外，α5-nAChR通过多种免疫相关因子途径对肺部免疫反应产生深远影响。在本综述中，我们重点探讨α5-nAChR在肺癌进展中的作用，这表明靶向α5-nAChR可为肺癌提供新的抗癌和免疫治疗策略。
